ADC Therapeutics SA (ADCT) ニュース

Form 8-K - Current report

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Jan...

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in 2L+ Diffuse Large B-Cell Lymphoma

ADC Therapeutics Announces Completion of Enrollment of Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in...

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial Evaluating ZYNLONTA® in Combination with Rituximab to Treat Relapsed/Refractory Follicular Lymphoma

ADC Therapeutics Announces The Lancet Haematology Publication of Data from Investigator-Initiated Trial...

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial

ADC Therapeutics to Provide Initial Data Update on LOTIS-7 Clinical Trial PR Newswire LAUSANNE, Switzerland...

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

ADC Therapeutics Makes Grants to New Employees Under Inducement Plan PR Newswire LAUSANNE, Switzerland, Dec...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational Update

ADC Therapeutics Reports Third Quarter and Year-to-Date 2024 Financial Results and Provides Operational...

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH Annual Meeting

ADC Therapeutics Announces Investigator-Initiated Study Abstracts Accepted for Presentation at the 66th ASH...

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics to Present at November Investor Conferences PR Newswire LAUSANNE, Switzerland, Nov. 4, 2024...